Breaking News

Frontage Labs Adds Senior Clinical Staff

July 2, 2013

Laskaris, Villasin to lead early phase expansion efforts

George Laskaris has been named senior director of Frontage Laboratories Biometrics Services. Mr. Laskaris has more than 20 years of programming, statistical and data management experience with pharmaceutical and CROs. In this new role, he will lead operational management, infrastructure development and growth strategies for the company’s clinical programming, statistics and data management groups.
Mr. Laskaris joins the company from PRA International, where he managed a team of statistical programmers. Previously, he worked at several global pharma companies, serving in a variety of management roles in clinical research positions.
Alma Villasin, RN, BSN, MBA, has been named director of Clinical Operations. She will be responsible for day-to-day oversight of clinical operations and staff training for all study activities, and for the company’s clinical operations expansion initiative.
Most recently, Ms. Villasin served as clinical operations director for Duke Clinical Research Unit (DCRU), where she oversaw the feasibility and conduct of Phase I-III trials. Prior to that, Ms. Villasin worked at Thomas Jefferson University as manager of the clinical trials groups, where she lead a research collaboration on global cardiovascular Phase II/III trials and developed an investigator network in key therapeutic areas such as cardiovascular, endocrinology and family medicine.
“I am delighted to welcome these two talented leaders to Frontage. I am confident they will enable Frontage to continually enhance our service offerings and offer valuable insights to our clients that help solve difficult development challenges, or optimize a clinical development pathway,” said Song Li, chairman and chief executive officer of Frontage Laboratories. “Our company foundation and success is built upon the efforts and commitment of our internal teams”
Frontage plans to expand its full-service early phase clinical services, which includes capabilities to conduct a broad range of clinical study types, as well as broadening protocol development, analysis methodology and reporting services supporting later phase trials and programs.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research